Symbols / IVA Stock $5.25 -2.78% Inventiva S.A.

Healthcare • Biotechnology • France • NGM
IVA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Stock Fundamentals
Scroll to Statements
Market Cap 1.09B Enterprise Value 1.22B Income -354.14M Sales 6.76M Book/sh -0.07 Cash/sh 0.48
Dividend Yield — Payout 0.00% Employees 69 IPO — P/E — Forward P/E -4.13
PEG — P/S 161.24 P/B -71.60 P/C — EV/EBITDA -9.22 EV/Sales 180.67
Quick Ratio 1.41 Current Ratio 3.16 Debt/Eq — LT Debt/Eq — EPS (ttm) -2.24 EPS next Y -1.27
EPS Growth — Revenue Growth -89.90% Earnings 2026-03-30 ROA -45.08% ROE — ROIC —
Gross Margin 99.68% Oper. Margin -67.11% Profit Margin 0.00% Shs Outstand 207.65M Shs Float 122.21M Short Float 0.23%
Short Ratio 1.56 Short Interest — 52W High 7.98 52W Low 2.85 Beta 0.95 Avg Volume 402.44K
Volume 141.95K Target Price $15.13 Recom Strong_buy Prev Close $5.40 Price $5.25 Change -2.78%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.13
Mean price target
2. Current target
$5.25
Latest analyst target
3. DCF / Fair value
$-17.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.25
Low
$8.80
High
$26.00
Mean
$15.13

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-19 init Truist Securities — → Buy $13
2026-01-28 init Barclays — → Overweight $18
2026-01-12 init Leerink Partners — → Outperform $12
2025-11-18 main Guggenheim Buy → Buy $11
2025-11-06 init Wolfe Research — → Outperform $13
2025-10-09 main HC Wainwright & Co. Buy → Buy $24
2025-09-30 main Canaccord Genuity Buy → Buy $20
2025-09-02 main Guggenheim Buy → Buy $13
2025-08-27 init Piper Sandler — → Overweight $26
2025-04-04 main Guggenheim Buy → Buy $9
2025-04-02 reit HC Wainwright & Co. Buy → Buy $13
2025-03-28 reit HC Wainwright & Co. Buy → Buy $13
2025-01-30 reit HC Wainwright & Co. Buy → Buy $13
2024-11-22 main Stifel Buy → Buy $17
2024-11-12 init UBS — → Neutral $3
2024-10-15 main HC Wainwright & Co. Buy → Buy $13
2024-09-26 main HC Wainwright & Co. Buy → Buy $14
2024-09-26 main Stifel Buy → Buy $20
2024-04-08 main Canaccord Genuity Buy → Buy $20
2024-04-01 reit HC Wainwright & Co. Buy → Buy $22
News
RSS: Latest IVA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4.48
-51.26%
9.20
-47.37%
17.48
+43.50%
12.18
Operating Revenue
4.48
-51.26%
9.20
-47.37%
17.48
+43.50%
12.18
Operating Expense
137.37
+33.12%
103.19
-14.11%
120.14
+74.03%
69.04
Research And Development
87.04
-4.22%
90.88
-17.39%
110.01
+81.93%
60.47
Selling General And Administration
53.89
+215.18%
17.10
+9.56%
15.61
+2.17%
15.28
Selling And Marketing Expense
4.84
+187.13%
1.69
-3.93%
1.75
-25.79%
2.37
General And Administrative Expense
49.05
+218.24%
15.41
+11.27%
13.85
+7.29%
12.91
Salaries And Wages
36.62
+506.36%
6.04
+21.60%
4.97
+18.74%
4.18
Other Gand A
10.88
+16.06%
9.37
+5.49%
8.88
+1.80%
8.73
Other Operating Expenses
-3.82
+30.33%
-5.49
+3.52%
-5.69
+17.94%
-6.93
Total Expenses
137.37
+33.12%
103.19
-14.11%
120.14
+74.03%
69.04
Operating Income
-132.88
-41.38%
-93.99
+8.45%
-102.67
-80.57%
-56.86
Total Operating Income As Reported
-141.01
-44.54%
-97.56
+5.02%
-102.71
-79.84%
-57.11
EBITDA
-317.33
-90.56%
-166.53
-63.19%
-102.04
-96.65%
-51.89
Normalized EBITDA
-127.12
-44.47%
-88.00
+12.99%
-101.14
-84.50%
-54.82
Reconciled Depreciation
3.22
-38.00%
5.20
+100.00%
2.60
+53.06%
1.70
EBIT
-320.55
-86.67%
-171.72
-64.11%
-104.64
-95.27%
-53.59
Total Unusual Items
-190.20
-142.20%
-78.53
-8577.35%
-0.91
-130.92%
2.93
Total Unusual Items Excluding Goodwill
-190.20
-142.20%
-78.53
-8577.35%
-0.91
-130.92%
2.93
Special Income Charges
-8.13
-127.77%
-3.57
-8011.36%
-0.04
+66.15%
-0.13
Impairment Of Capital Assets
—
1.79
0.00
0.00
Restructuring And Mergern Acquisition
8.41
+126.24%
3.72
+8352.27%
0.04
-63.64%
0.12
Write Off
—
0.37
0.00
0.00
Net Income
-354.14
-92.24%
-184.21
-66.82%
-110.43
-103.46%
-54.27
Pretax Income
-354.11
-92.56%
-183.90
-67.46%
-109.82
-102.27%
-54.29
Net Non Operating Interest Income Expense
-30.68
-177.15%
-11.07
-161.49%
-4.23
-1062.91%
-0.36
Interest Expense Non Operating
33.56
+175.61%
12.18
+135.19%
5.18
+632.39%
0.71
Net Interest Income
-30.68
-177.15%
-11.07
-161.49%
-4.23
-1062.91%
-0.36
Interest Expense
33.56
+175.61%
12.18
+135.19%
5.18
+632.39%
0.71
Interest Income Non Operating
2.94
+157.66%
1.14
+15.34%
0.99
+154.10%
0.39
Interest Income
2.94
+157.66%
1.14
+15.34%
0.99
+154.10%
0.39
Other Income Expense
-190.55
-141.69%
-78.84
-2600.10%
-2.92
-199.76%
2.93
Gain On Sale Of Security
-182.07
-142.89%
-74.96
-8606.27%
-0.86
-128.16%
3.06
Tax Provision
0.02
-92.97%
0.31
-48.43%
0.61
+3135.00%
-0.02
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+41566.67%
0.00
Tax Effect Of Unusual Items
-47.55
-142.20%
-19.63
-8577.35%
-0.23
-12982.93%
0.00
Net Income Including Noncontrolling Interests
-354.13
-92.24%
-184.21
-66.82%
-110.42
-103.46%
-54.27
Net Income From Continuing Operation Net Minority Interest
-354.14
-92.24%
-184.21
-66.82%
-110.43
-103.46%
-54.27
Net Income From Continuing And Discontinued Operation
-354.14
-92.24%
-184.21
-66.82%
-110.43
-103.46%
-54.27
Net Income Continuous Operations
-354.13
-92.24%
-184.21
-66.82%
-110.42
-103.46%
-54.27
Normalized Income
-211.49
-68.76%
-125.31
-14.18%
-109.75
-91.87%
-57.20
Net Income Common Stockholders
-354.14
-92.24%
-184.21
-66.82%
-110.43
-103.46%
-54.27
Diluted EPS
-1.90
+38.31%
-3.08
-26.75%
-2.43
-85.50%
-1.31
Basic EPS
-1.90
+38.31%
-3.08
-26.75%
-2.43
-85.50%
-1.31
Basic Average Shares
186.39
+211.80%
59.78
+31.81%
45.35
+9.41%
41.45
Diluted Average Shares
186.39
+211.80%
59.78
+31.81%
45.35
+9.41%
41.45
Diluted NI Availto Com Stockholders
-354.14
-92.24%
-184.21
-66.82%
-110.43
-103.46%
-54.27
Depreciation Amortization Depletion Income Statement
0.25
-63.54%
0.69
+232.06%
0.21
-5.00%
0.22
Depreciation And Amortization In Income Statement
0.25
-63.54%
0.69
+232.06%
0.21
-5.00%
0.22
Earnings From Equity Interest
-0.35
-11.82%
-0.31
+84.47%
-2.02
0.00
Gain On Sale Of PPE
0.28
+90.00%
0.15
0.00
+100.00%
-0.01
Insurance And Claims
1.55
0.00
0.00
—
Other Taxes
—
—
0.00
0.00
Provision For Doubtful Accounts
—
—
0.00
0.00
Total Other Finance Cost
0.06
+73.53%
0.03
-26.09%
0.05
-2.13%
0.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
249.51
+109.73%
118.97
+71.03%
69.56
Current Assets
244.47
+119.23%
111.51
+131.40%
48.19
Cash Cash Equivalents And Short Term Investments
230.87
+139.09%
96.56
+257.80%
26.99
Cash And Cash Equivalents
99.31
+2.85%
96.56
+258.73%
26.92
Cash Equivalents
82.63
+16.95%
70.66
+293.99%
17.93
Cash Financial
16.68
-35.60%
25.91
+188.35%
8.98
Other Short Term Investments
131.56
0.00
-100.00%
0.07
Receivables
9.12
-24.97%
12.16
-22.60%
15.71
Accounts Receivable
2.02
+279.66%
0.53
-86.05%
3.81
Other Receivables
1.68
+2.82%
1.63
+9.99%
1.48
Taxes Receivable
5.43
-45.69%
10.00
-4.05%
10.42
Inventory
0.00
0.00
-100.00%
0.42
Prepaid Assets
3.95
+61.83%
2.44
-47.55%
4.66
Hedging Assets Current
—
—
—
Other Current Assets
0.53
+50.72%
0.35
-17.10%
0.42
Total Non Current Assets
5.04
-32.35%
7.46
-65.12%
21.37
Net PPE
2.98
-40.44%
5.00
-45.16%
9.13
Gross PPE
19.94
-1.27%
20.20
+1.80%
19.84
Accumulated Depreciation
-16.96
-11.63%
-15.19
-41.82%
-10.71
Properties
0.00
0.00
0.00
Land And Improvements
0.17
+0.00%
0.17
+0.00%
0.17
Buildings And Improvements
3.47
-0.03%
3.47
+0.00%
3.47
Machinery Furniture Equipment
4.78
-17.91%
5.82
+3.84%
5.60
Construction In Progress
0.00
-100.00%
0.02
-82.61%
0.12
Other Properties
11.52
+7.52%
10.72
+2.27%
10.48
Goodwill And Other Intangible Assets
0.18
+281.25%
0.05
-91.14%
0.54
Other Intangible Assets
0.18
+281.25%
0.05
-91.14%
0.54
Investments And Advances
0.53
-53.73%
1.14
-20.07%
1.43
Long Term Equity Investment
0.53
-53.73%
1.14
-20.07%
1.43
Non Current Accounts Receivable
—
—
—
Non Current Deferred Assets
0.19
-11.98%
0.22
-3.56%
0.23
Non Current Deferred Taxes Assets
0.19
-11.98%
0.22
-3.56%
0.23
Non Current Prepaid Assets
1.16
+10.98%
1.05
-89.59%
10.05
Other Non Current Assets
—
—
—
Total Liabilities Net Minority Interest
278.03
+23.23%
225.61
+122.08%
101.59
Current Liabilities
77.38
-35.91%
120.73
+140.70%
50.16
Payables And Accrued Expenses
44.00
+6.12%
41.46
-7.54%
44.84
Payables
33.26
-16.27%
39.72
-8.27%
43.30
Accounts Payable
26.02
-20.83%
32.86
-12.78%
37.68
Other Payable
5.47
+86.44%
2.94
+55.13%
1.89
Current Accrued Expenses
10.74
+516.83%
1.74
+13.05%
1.54
Employee Benefits
0.76
-57.15%
1.76
+13.02%
1.56
Total Tax Payable
1.77
-54.89%
3.92
+5.12%
3.73
Current Debt And Capital Lease Obligation
32.31
+450.58%
5.87
+10.55%
5.31
Current Debt
30.27
+804.18%
3.35
+11.23%
3.01
Other Current Borrowings
30.27
+804.18%
3.35
+11.23%
3.01
Current Capital Lease Obligation
2.04
-19.21%
2.52
+9.66%
2.30
Current Deferred Liabilities
0.00
0.00
-100.00%
0.01
Current Deferred Revenue
0.00
0.00
-100.00%
0.01
Other Current Liabilities
0.00
-100.00%
73.40
—
Total Non Current Liabilities Net Minority Interest
200.66
+91.32%
104.88
+103.92%
51.43
Long Term Debt And Capital Lease Obligation
27.55
-43.15%
48.46
+50.59%
32.18
Long Term Debt
26.82
-42.11%
46.33
+65.96%
27.91
Long Term Capital Lease Obligation
0.73
-65.57%
2.13
-49.96%
4.27
Non Current Pension And Other Postretirement Benefit Plans
0.76
-57.15%
1.76
+13.02%
1.56
Non Current Deferred Liabilities
0.13
+17.76%
0.11
+52.86%
0.07
Non Current Deferred Revenue
0.13
+17.76%
0.11
+52.86%
0.07
Other Non Current Liabilities
52.84
+74.75%
30.24
+310.88%
7.36
Stockholders Equity
-28.52
+73.26%
-106.65
-232.95%
-32.03
Common Stock Equity
-28.52
+73.26%
-106.65
-232.95%
-32.03
Capital Stock
1.93
+101.88%
0.96
+83.69%
0.52
Common Stock
1.93
+101.88%
0.96
+83.69%
0.52
Share Issued
191.99
+100.44%
95.78
+83.42%
52.22
Ordinary Shares Number
191.93
+100.63%
95.66
+83.56%
52.12
Treasury Shares Number
0.06
-50.59%
0.12
+13.58%
0.11
Additional Paid In Capital
528.23
+112.00%
249.16
+23.43%
201.86
Retained Earnings
-354.14
-92.24%
-184.21
-66.82%
-110.43
Gains Losses Not Affecting Retained Earnings
-204.55
-18.54%
-172.55
-39.17%
-123.99
Other Equity Adjustments
-205.18
-18.50%
-173.15
-38.98%
-124.58
Total Equity Gross Minority Interest
-28.52
+73.26%
-106.65
-232.95%
-32.03
Total Capitalization
-1.71
+97.17%
-60.32
-1365.14%
-4.12
Working Capital
167.09
+1912.27%
-9.22
-368.26%
-1.97
Invested Capital
28.57
+150.14%
-56.97
-5046.52%
-1.11
Total Debt
59.86
+10.18%
54.33
+44.92%
37.49
Net Debt
—
—
4.01
Capital Lease Obligations
2.77
-40.47%
4.66
-29.09%
6.57
Net Tangible Assets
-28.70
+73.10%
-106.69
-227.55%
-32.57
Tangible Book Value
-28.70
+73.10%
-106.69
-227.55%
-32.57
Available For Sale Securities
—
—
9.00
Current Deferred Taxes Liabilities
—
—
0.00
Current Provisions
1.07
—
—
Derivative Product Liabilities
119.39
+390.99%
24.32
+136.87%
10.27
Foreign Currency Translation Adjustments
0.64
+6.00%
0.60
+0.67%
0.60
Investmentin Financial Assets
—
—
9.00
Other Inventories
—
—
0.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-104.88
-22.06%
-85.93
-5.29%
-81.61
-81.66%
-44.93
Cash Flow From Continuing Operating Activities
-104.89
-22.06%
-85.93
-5.28%
-81.61
-81.66%
-44.93
Net Income From Continuing Operations
-354.14
-92.24%
-184.21
-66.82%
-110.43
-103.46%
-54.27
Depreciation Amortization Depletion
3.22
-38.00%
5.20
+100.00%
2.60
+53.06%
1.70
Depreciation
3.22
-38.00%
5.20
+100.00%
2.60
+53.06%
1.70
Depreciation And Amortization
3.22
-38.00%
5.20
+100.00%
2.60
+53.06%
1.70
Other Non Cash Items
213.14
+142.73%
87.81
+3991.89%
2.15
+98.34%
1.08
Stock Based Compensation
26.77
+647.74%
3.58
-9.80%
3.97
+78.94%
2.22
Deferred Tax
-2.30
+52.13%
-4.80
-1.24%
-4.74
+9.88%
-5.26
Deferred Income Tax
-2.30
+52.13%
-4.80
-1.24%
-4.74
+9.88%
-5.26
Operating Gains Losses
1.74
+435.14%
-0.52
-122.40%
2.31
+574.05%
0.34
Net Foreign Currency Exchange Gain Loss
1.36
+220.96%
-1.13
-479.12%
0.30
-13.41%
0.34
Gain Loss On Sale Of PPE
0.02
-94.74%
0.46
0.00
0.00
Change In Working Capital
1.77
+5.18%
1.68
-90.30%
17.31
+202.94%
5.71
Change In Receivables
0.85
-69.71%
2.81
+148.04%
-5.84
-251.95%
3.84
Change In Inventory
0.00
-100.00%
0.42
+1047.73%
-0.04
-331.58%
0.02
Change In Payables And Accrued Expense
2.56
+176.57%
-3.34
-116.69%
20.00
+465.83%
3.54
Change In Payable
2.56
+176.57%
-3.34
-116.69%
20.00
+465.83%
3.54
Change In Other Working Capital
-1.64
-191.42%
1.79
-43.76%
3.19
+289.32%
-1.69
Investing Cash Flow
-133.19
-1623.00%
8.74
+213.12%
-7.73
-187.18%
8.87
Cash Flow From Continuing Investing Activities
-133.19
-1622.98%
8.74
+213.12%
-7.73
-187.19%
8.87
Net PPE Purchase And Sale
-0.25
+25.83%
-0.33
+18.58%
-0.41
+21.35%
-0.52
Purchase Of PPE
-0.25
+25.83%
-0.33
+38.33%
-0.54
+3.74%
-0.56
Sale Of PPE
0.00
0.00
-100.00%
0.13
+219.51%
0.04
Capital Expenditure
-0.25
+25.83%
-0.33
+38.33%
-0.54
+3.74%
-0.56
Net Investment Purchase And Sale
-132.94
-1564.40%
9.08
+223.98%
-7.32
-178.00%
9.39
Purchase Of Investment
-132.94
—
-8.30
-829900.00%
-0.00
Sale Of Investment
—
9.08
+828.22%
0.98
-89.58%
9.39
Net Other Investing Changes
-0.00
—
—
0.00
Financing Cash Flow
241.29
+65.73%
145.59
+400.64%
29.08
-21.97%
37.27
Cash Flow From Continuing Financing Activities
241.28
+65.73%
145.59
+400.64%
29.08
-21.97%
37.27
Net Issuance Payments Of Debt
-5.98
-130.01%
19.92
+586.31%
-4.10
-114.41%
28.44
Issuance Of Debt
0.00
-100.00%
24.92
0.00
-100.00%
30.21
Repayment Of Debt
-5.98
-19.79%
-4.99
-21.85%
-4.10
-131.73%
-1.77
Long Term Debt Issuance
0.00
-100.00%
24.92
0.00
-100.00%
30.21
Long Term Debt Payments
-5.98
-19.79%
-4.99
-21.85%
-4.10
-131.73%
-1.77
Net Long Term Debt Issuance
-5.98
-130.01%
19.92
+586.31%
-4.10
-114.41%
28.44
Net Common Stock Issuance
206.44
+260.04%
57.34
+87.45%
30.59
+246.54%
8.83
Cash Dividends Paid
0.00
0.00
0.00
—
Proceeds From Stock Option Exercised
58.21
-0.05%
58.23
0.00
0.00
Net Other Financing Charges
-17.13
-269.70%
10.10
+289.96%
2.59
-91.43%
30.21
Changes In Cash
3.22
-95.30%
68.41
+213.52%
-60.26
-5088.66%
1.21
Effect Of Exchange Rate Changes
-0.47
-137.83%
1.24
+177.98%
0.45
+143.41%
-1.02
Beginning Cash Position
96.56
+258.73%
26.92
-68.97%
86.74
+0.21%
86.55
End Cash Position
99.31
+2.85%
96.56
+258.73%
26.92
-68.97%
86.74
Free Cash Flow
-105.13
-21.88%
-86.26
-5.00%
-82.15
-80.60%
-45.49
Common Stock Issuance
206.44
+260.04%
57.34
+87.45%
30.59
+246.54%
8.83
Earnings Losses From Equity Investments
0.35
+130.26%
0.15
-92.46%
2.02
0.00
Interest Paid CFF
-0.25
0.00
0.00
—
Issuance Of Capital Stock
206.44
+260.04%
57.34
+87.45%
30.59
+246.54%
8.83
Taxes Refund Paid
4.92
-7.84%
5.33
+2.16%
5.22
+46.92%
3.55
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category